Related Experiment Video
Updated: Jan 15, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Noninvasive Prediction Models of First Decompensation in Compensated Advanced Chronic Liver Disease: A Meta-Analysis
Angus W Jeffrey1, James Chen2, Andrew Chin3
1Department of Medicine, University of Western Australia, Perth, Australia; Department of Hepatology, Sir Charles Gairdner Hospital, Perth, Australia; Liver Transplant Unit, Austin Hospital, Melbourne, Australia.
Noninvasive prediction models (NITs) accurately identify patients with compensated advanced chronic liver disease (cACLD) at risk of decompensation. cACLD-specific models, like SAVE and ABC scores, show the best predictive performance.
Area of Science:
- Hepatology
- Internal Medicine
- Clinical Prediction Models
Background:
- Compensated advanced chronic liver disease (cACLD) carries a significant risk of hepatic decompensation.
- Accurate identification of high-risk patients is crucial for timely intervention.
Purpose of the Study:
- To critically appraise noninvasive prediction models (NITs) for identifying cACLD patients at increased risk of hepatic decompensation.
- To determine the accuracy and reliability of existing NITs.
Main Methods:
- Systematic review and meta-analysis of published articles until February 2025.
- Included studies evaluated prognostic models combining at least two noninvasive markers.
- Extracted data included C-statistics, AUC, and model calibration.
Main Results:
- 30 studies with 47,647 participants were included, evaluating 39 prognostic models.
- Models specifically developed and validated in cACLD, such as SAVE (C-statistic=0.87) and ABC scores (C-statistic=0.85), demonstrated superior prediction.
- Limited validation and calibration were noted across most models.
Conclusions:
- cACLD-specific NITs are the preferred choice for predicting decompensation.
- Future research must prioritize robust validation, calibration, and external validation with standardized endpoints for clinical reliability.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

